Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

91
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
91
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

153
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
153
Proteomics01:33

Proteomics

7.3K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.3K
  1. Home
  3. Exploring Candidate Biomarkers For Rheumatoid Arthritis Through Cardiovascular And Cardiometabolic Serum Proteome Profiling.
  1. Home
  3. Exploring Candidate Biomarkers For Rheumatoid Arthritis Through Cardiovascular And Cardiometabolic Serum Proteome Profiling.

Related Experiment Video

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.2K

Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome

Laura Cuesta-López1, Alejandro Escudero-Contreras1, Yas Hanaee1,2

  • 1Rheumatology Service, Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Frontiers in Immunology
|February 29, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Rheumatoid arthritis (RA) patients have increased cardiovascular disease risk. This study identified protein biomarkers for RA and cardiovascular disease, and showed how methotrexate and tofacitinib therapies impact these proteins.

Keywords:
Olinkbiomarkersmethotrexateproximity extension assay (PEA)rheumatoid arthritistofacitinib

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.7K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K

Related Experiment Videos

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.2K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.7K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K

Area of Science:

  • Proteomics
  • Immunology
  • Cardiovascular Medicine

Background:

  • Rheumatoid arthritis (RA) patients face a heightened risk of cardiovascular disease (CVD), often influenced by therapeutic interventions.
  • Understanding the cardiovascular and cardiometabolic proteome in RA is crucial for identifying novel biomarkers and elucidating associated biological pathways.

Purpose of the Study:

  • To identify protein biomarkers associated with cardiovascular disease in rheumatoid arthritis patients.
  • To investigate the impact of methotrexate and tofacitinib therapies on the proteomic profile of RA patients.
  • To explore potential protein markers predictive of treatment response.

Main Methods:

  • Serum protein profiling of 184 proteins using Olink technology in two RA cohorts (newly diagnosed and established disease) and matched healthy donors (HDs).
  • Longitudinal analysis of RA patients treated with methotrexate or tofacitinib for 6 months.
  • Clinical variables, including disease activity score 28 (DAS28), were recorded.

    • Main Results:

    • Elevated levels of 75 proteins were observed in RA patients, potentially linked to CVD. Twenty proteins were commonly altered in both RA cohorts, with CTSL1, SORT1, SAA4, TNFRSF10A, ST6GAL1, and CCL18 discriminating RA from HDs.
    • Methotrexate reduced 13 proteins and tofacitinib modulated 10 proteins, associated with decreased DAS28. SAA4 and BNP levels predicted methotrexate non-response, while IL6 changes indicated response.
    • Treatment response to tofacitinib correlated with baseline LOX1 and CNDP1 levels and changes in SAA4 and TIMD4.

    Conclusions:

    • This study identifies key protein alterations in RA linked to CVD and proposes candidate biomarkers for differentiating RA patients from healthy individuals.
    • Methotrexate and tofacitinib differentially modulate these protein levels, with distinct changes correlating to treatment response.
    • SAA4 emerges as a potential candidate biomarker for predicting response to RA therapies.